Development of SARS-CoV-2 replicons for the ancestral virus and variant of concern Delta for antiviral screening.
M. Erdmann, M. Kavanagh Williamson, T. Jearanaiwitayakul, J. Bazire, D. A. Matthews, A. D. Davidson
The paper develops SARS-CoV-2 replicons for the ancestral virus and Delta variant to screen antiviral compounds, showing sensitivity to remdesivir.
bioRxiv · Oct 11, 2022Microbiology